Matching articles for "KY jelly"
Imvexxy - Another Estradiol Vaginal Insert for Dyspareunia
The Medical Letter on Drugs and Therapeutics • September 10, 2018; (Issue 1555)
The FDA has approved an estradiol softgel vaginal
insert (Imvexxy – TherapeuticsMD) for treatment of
postmenopausal women with moderate to severe
dyspareunia due to vulvovaginal atrophy (VVA).
Imvexxy is...
The FDA has approved an estradiol softgel vaginal
insert (Imvexxy – TherapeuticsMD) for treatment of
postmenopausal women with moderate to severe
dyspareunia due to vulvovaginal atrophy (VVA).
Imvexxy is the second estradiol vaginal insert to be
approved in the US; Vagifem, an intravaginal tablet
formulation, was the first. Vagifem and Imvexxy are
both available in inserts containing 10 mcg of estradiol;
Imvexxy is also available in a 4-mcg strength.
Ospemifene (Osphena) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • July 8, 2013; (Issue 1420)
The FDA has approved ospemifene (os pem’ i feen;
Osphena – Shionogi), an estrogen agonist/antagonist,
for oral treatment of moderate to severe dyspareunia in
postmenopausal women. Ospemifene is the...
The FDA has approved ospemifene (os pem’ i feen;
Osphena – Shionogi), an estrogen agonist/antagonist,
for oral treatment of moderate to severe dyspareunia in
postmenopausal women. Ospemifene is the fourth estrogen
agonist/antagonist to be marketed in the US, but it is
the only one that has an estrogen-like effect on vaginal
epithelium. The other three, tamoxifen (Nolvadex, and
generics), toremifene (Fareston), and raloxifene (Evista),
are used for treatment and prevention of breast cancer
and osteoporosis.
Drugs for Female Sexual Dysfunction
The Medical Letter on Drugs and Therapeutics • December 13, 2010; (Issue 1353)
Sexual complaints related to desire, arousal, orgasm
and painful intercourse are common in women. Since
the last Medical Letter article on this subject, some
new information has become...
Sexual complaints related to desire, arousal, orgasm
and painful intercourse are common in women. Since
the last Medical Letter article on this subject, some
new information has become available.
Drugs for Female Sexual Dysfunction
The Medical Letter on Drugs and Therapeutics • April 23, 2007; (Issue 1259)
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used...
Sexual complaints related to desire, arousal, orgasm and pain are common in women. No drugs are approved by the FDA for any of these indications, but many are used off-label.